J.P. Marvel Investment Advisors LLC Has $10.05 Million Position in Johnson & Johnson (JNJ)

J.P. Marvel Investment Advisors LLC trimmed its stake in Johnson & Johnson (NYSE:JNJ) by 0.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 75,949 shares of the company’s stock after selling 318 shares during the period. Johnson & Johnson makes up approximately 3.3% of J.P. Marvel Investment Advisors LLC’s portfolio, making the stock its 3rd biggest holding. J.P. Marvel Investment Advisors LLC’s holdings in Johnson & Johnson were worth $10,047,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of JNJ. Harding Loevner LP bought a new position in shares of Johnson & Johnson in the second quarter worth approximately $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its holdings in shares of Johnson & Johnson by 29.9% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares during the last quarter. Lenox Wealth Advisors Inc. grew its holdings in shares of Johnson & Johnson by 0.6% in the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after purchasing an additional 5 shares during the last quarter. Mountain Capital Investment Advisors Inc bought a new position in shares of Johnson & Johnson in the second quarter worth approximately $124,000. Finally, Shine Investment Advisory Services Inc. bought a new position in shares of Johnson & Johnson in the second quarter worth approximately $177,000. Institutional investors own 65.89% of the company’s stock.

Johnson & Johnson (NYSE:JNJ) opened at $142.46 on Friday. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36. The company has a market capitalization of $382,721.66, a price-to-earnings ratio of 19.95, a price-to-earnings-growth ratio of 2.90 and a beta of 0.80. Johnson & Johnson has a 52-week low of $110.76 and a 52-week high of $144.35.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The firm had revenue of $19.65 billion during the quarter, compared to the consensus estimate of $19.29 billion. During the same period last year, the company earned $1.68 earnings per share. The company’s revenue was up 10.3% on a year-over-year basis. equities research analysts forecast that Johnson & Johnson will post 7.28 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th were issued a dividend of $0.84 per share. The ex-dividend date was Monday, November 27th. This represents a $3.36 annualized dividend and a dividend yield of 2.36%. Johnson & Johnson’s payout ratio is presently 58.33%.

Several research analysts have recently issued reports on the stock. Zacks Investment Research cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Tuesday, December 12th. Citigroup started coverage on Johnson & Johnson in a research note on Monday, September 25th. They issued a “neutral” rating and a $140.00 price target for the company. BMO Capital Markets reaffirmed a “positive” rating and issued a $152.00 price target (up previously from $145.00) on shares of Johnson & Johnson in a research note on Wednesday, October 18th. Jefferies Group raised their price target on Johnson & Johnson from $157.00 to $160.00 and gave the stock a “buy” rating in a research note on Monday, October 16th. Finally, Royal Bank of Canada raised their price target on Johnson & Johnson from $144.00 to $147.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 18th. Four research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $145.04.

WARNING: “J.P. Marvel Investment Advisors LLC Has $10.05 Million Position in Johnson & Johnson (JNJ)” was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://sportsperspectives.com/2017/12/17/j-p-marvel-investment-advisors-llc-has-10-05-million-position-in-johnson-johnson-jnj.html.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply